Özet:

Introduction and Purpose: Acute myeloid leukemia (AML) is an increasing frequency of hematological malignity in the elderly population. Low-intensity treatments and support treatments are provided as appropriate options in humid and elderly patients. Over the years, positive developments have occurred in the field of therapy with the use of hypometylating agents. The aim of our study in our center is to investigate the effectiveness of the etopocytes and cytosine arabinozide (AraC) enhanced combination regime (AZA) that we apply as a treatment protocol in our senior AML patients. Methods and Requirements: The new diagnosis that is not suitable for intensive treatments due to the advanced age and performance conditions that we have followed has been retrospective examined in the AML patients. Two groups were formed in terms of age, performance, comorbidity, one group (n: 32) was treated with the combination of AZA-etoposit-AraC, while the other group (n: 32) was treated with low doses of sitosine arabinozide and/or hydroxyure. The groups are compared with each other in terms of hematological parameters, tracking time, response status and survival. Foundations: In eight patients treated with a combination of azacitidine, a full response or a minimum partial response was obtained (p: 0.011). While 30 day mortality is significantly high in low-intensity treatment, no difference has been found in both groups in terms of overall survival (respectively p: 0.005 and p: 0.092) DEVELOPMENT and RESULTS: Non-intense therapies, older and disadvantaged patients should be encouraged in terms of treatment. Especially in developing countries, combinations of molecules that are expensive and difficult to reach with hypothetical drugs, as well as combinations of cheap and easy to access molecules are needed. We recommend the combination treatment of azacitidine-etoposit-sitozin arabinozide that provides a response advantage to the patient’s selection.

Anahtar Kelimeler: